BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.18 CNY | -4.78% |
|
-9.77% | -23.76% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -23.76% | 824M | - | ||
| +26.37% | 48.16B | B- | ||
| -1.01% | 41.73B | B | ||
| +45.09% | 41.03B | A | ||
| -5.31% | 28.77B | C | ||
| +9.34% | 25.59B | B- | ||
| -21.69% | 18.96B | B | ||
| +6.23% | 12.92B | B+ | ||
| +26.99% | 12.03B | C+ | ||
| -3.38% | 11.77B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- 688621 Stock
- Ratings Beijing Sun-Novo Pharmaceutical Research Co., Ltd.